New York State Common Retirement Fund Corvus Pharmaceuticals, Inc. Transaction History
New York State Common Retirement Fund
- $74.9 Billion
- Q3 2025
A detailed history of New York State Common Retirement Fund transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, New York State Common Retirement Fund holds 18,800 shares of CRVS stock, worth $164,876. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,800
Previous 23,800
21.01%
Holding current value
$164,876
Previous $95,000
41.05%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CRVS
# of Institutions
109Shares Held
38.3MCall Options Held
198KPut Options Held
167K-
Orbimed Advisors LLC San Diego, CA7.17MShares$62.8 Million1.75% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct6.45MShares$56.6 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.47MShares$30.4 Million0.0% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$28.7 Million16.52% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$23.5 Million0.26% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $408M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...